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Asthma is a complex disease linked to various pathophysiological events including 
the activity of proteinases. The multifunctional A Disintegrin And Metalloproteinases 
(ADAMs) displaying the ability to cleave membrane-bound mediators or cytokines 
appear to be key mediators in various inflammatory processes. In the present study, 
we have investigated ADAM-8 expression and production in a mouse model of 
allergen-induced airway inflammation. In allergen-exposed animals, increased 
expression of ADAM-8 was found in the lung parenchyma and in dendritic cells 
purified from the lungs. The potential role of ADAM-8 in the development of allergen-
induced airway inflammation was further investigated by the use of an anti-ADAM-8 
antibody and ADAM-8 knock-out animals. We observed a decrease in allergen-
induced acute inflammation both in BALF and the peribronchial area in anti-ADAM-8 
antibody-treated mice and in ADAM-8 deficient mice (ADAM-8-/-) after allergen 
exposure. ADAM-8 depletion led to a significant decrease of the CD11c+ lung 
dendritic cells. We also report lower levels of CCL11 and CCL22 production in 
antibody-treated mice and ADAM-8-/- mice that might be explained by decreased 
eosinophilic inflammation and lower numbers of dendritic cells, respectively. In 
conclusion, ADAM-8 appears to favour allergen-induced acute airway inflammation 






Asthma is mainly characterized by chronic bronchial inflammation and 
hyperresponsiveness [1, 2]. The disease phenotype in humans encompasses 
generally repeated episodes of non permanent airway obstruction along with 
wheezing, breathlessness and cough. Mouse models of asthma mimic most of these 
human asthma features and provide valuable tools for deciphering disease 
mechanisms [3]. Such mouse models have proven valuable for elucidating the 
implication of specific gene products, such as matrix proteinases. Therefore, several 
research groups have studied the asthmatic phenotype by using knock-out animals 
and reported that MMP-9 depleted mice display a lower cell infiltration and bronchial 
responsiveness upon allergen exposure [4]. In sharp contrast, MMP-8 deficiency 
promotes a neutrophilic inflammation in the airways [5] and MMP-2 deficiency 
induces inflammatory cell accumulation in lung parenchyma responsible for asphyxia 
in some animals [6]. 
ADAMs (A Disintegrin And Metalloproteinases) belong to the metzincin superfamily 
of proteinases. The typical structure of ADAM proteinases consists of 
metalloproteinase, disintegrin, and cytoplasmic domains which endow the protein 
with catalytic activity, adhesion properties, and potentially signaling functions [7-10]. 
Light was shed on the potential role of ADAM proteinases in asthma by a genetic 
association study demonstrating a link between increased risk of asthma 
development and polymorphisms in the ADAM-33 gene [11]. It was also reported that 
ADAM-33 gene expression correlates with asthma severity [12].  ADAM-8 is another 
member of the ADAM family displaying some structural similarities with ADAM-33. 
ADAM-8 has been first cloned from mouse macrophages [13] and is expressed at 
baseline or after stimulation by a wide range of cell types including neurons, 
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osteoclasts, bronchial epithelial cells and cells of the immune system (eosinophils, 
polymorphonuclear leukocytes (PMN), monocytes, macrophages, dendritic cells and 
B lymphocytes) [13-17]. ADAM-8 is implicated in various complex biological 
processes such as neurodegenerative inflammation and osteoclastogenesis [18, 19]. 
Moreover, two distinct studies based on a wide genome microarray have shown that 
ADAM-8 mRNA expression appears to be increased in asthma [20, 21]. More 
recently, transgenic mice overexpressing a soluble form of ADAM-8 (sADAM-8) in 
liver tissue showed less cellular infiltration in an allergen-induced model of lung 
inflammation, suggesting that sADAM-8 might play a role as inflammation inhibitor 
[22]. Known biological functions of ADAM-8 are to date restricted to cell fusion and 
adhesion [23]. ADAM-8 also appears to be a sheddase and cleaves CD23, neural 
cell adhesion molecule close homologue of L1 (CHL1), beta-amyloid precursor 
protein (APP), L-selectin, vascular cell adhesion molecule-1 (VCAM-1), and myelin 
basic protein (MBP) while there is also evidence for a possible cleavage of pro-tumor 
necrosis factor (TNF) α and CD16 [24, 25] rendering plausible a role as inflammation 
modulator for this proteinase  [25-27]. However, the question of whether ADAM-8 is 
involved in the development of asthma phenotype remains unanswered. 
In this study, we demonstrate through both genetic and antibody-based approaches 
that ADAM-8 is a key mediator for the development of asthma-linked inflammation. 
We describe that ADAM-8 depletion (transgenic mice deficient for ADAM-8) and 
injected antibodies raised against ADAM-8 impair the development of airway 
inflammation after allergen exposure. We also explored the mechanisms implicating 
ADAM-8 and report that ADAM-8 depletion modifies dendritic cell recruitment and 
production of key cytokines contributing to the network of interactions leading to 




ADAM-8 expression and production in lungs of mice acutely exposed to allergens 
In order to investigate ADAM-8 expression in an experimental model of asthma, male 
Balb/c mice were sensitized and subsequently exposed to ovalbumin (OVA) for 5 
days. As expected, mice exposed to OVA showed higher BALF eosinophil 
percentages and peribronchial inflammation as compared to mice exposed to PBS 
(eosinophil percentage: 1.700±1.361 in sham-exposed mice versus 56.187±6.255 in 
allergen-exposed mice, p<0.0001; inflammation score: 0.325±0.067 in sham-exposed 
mice versus 1.161±0.084 in allergen-exposed mice, p<0.0001). ADAM-8 was 
significantly upregulated at mRNA level in lung parenchyma of mice acutely exposed 
to allergens as compared to controls (figure 1A and C). Moreover, ADAM-8 protein 
production was also significantly increased in OVA-exposed mice as assessed by 
Western blotting and immunohistochemistry (figure 1B, D and E). Interestingly, the 
immunohistochemical analysis revealed that ADAM-8 stained cells mostly 
correspond to inflammatory cells such as eosinophils and macrophages located in 
the peribronchial area (figure 1E). 
ADAM-8 expression and production in chronic allergen-induced remodeling  
In order to further investigate ADAM-8 expression and production in a chronic 
remodeling model of asthma, male Balb/c mice were sensitized and subsequently 
exposed to OVA for 5 days per week (odd weeks) from days 22 to 96 (eosinophil 
percentage: 4.033±0.704 in sham-exposed mice versus 24.600±1.613 in allergen-
exposed mice, p<0.0001; inflammation score: 0.593±0.096 in sham-exposed mice 
versus 1.129±0.061 in allergen-exposed mice, p<0.05; glandular hyperplasia 
expressed in positive cells percentage: 0.062±0.062 in sham-exposed mice versus 
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33.640±4.363 in allergen-exposed mice, p<0.0001; basement membrane collagen: 
0.654±0.046 in sham-exposed mice versus 1.444±0.070 in allergen-exposed mice, 
p<0.0001). In this long-term model, mRNA levels of ADAM-8 were only poorly 
detectable (figure 1A) and the ADAM-8 protein production was very weak (figure 1B). 
Moreover, no significant difference between mice exposed to allergen or not was 
observed by RT-PCR and Western blotting.  
ADAM-8 blockade by antibody treatment 
In order to assess the implication of ADAM-8 in asthma-related acute inflammation, 
Balb/c mice were treated with an anti-ADAM-8 antibody for 3 days while a control 
isotype was injected to control Balb/c mice. Two hours after antibody injection, mice 
were exposed to OVA by aerosols. As shown in table 1 and figure 2A, eosinophil 
percentages in BALF were significantly decreased upon anti-ADAM-8 antibody 
treatment as compared to control mice treated with control isotype (p<0.05). In 
peribronchial areas, acute allergen-induced inflammation was also decreased in anti-
ADAM-8-treated mice (inflammation score: 1.080±0.160 in mice treated by control 
isotype versus 0.500±0.150 after anti-ADAM-8 antibody). Peribronchial eosinophilic 
inflammation was also significantly lower in anti-ADAM-8-treated mice (p< 0.0005) 
(figure 2B). Amounts of detectable ADAM-8 protein were strongly decreased in lung 
parenchyma of anti-ADAM-8-treated mice as assessed by Western blot (figure 2C). 
Moreover, decrease of eosinophilia BALF was assessed in both Th2-prone mice 
(Balb/c) and non Th2-prone (C57Bl/6) and found to be similar (figure 2D). 
Acute allergen-induced inflammation in ADAM-8-/- animals 
We also applied the allergen-induced acute inflammation model to ADAM-8 deficient 
mice (ADAM-8-/-) and wild-type counterparts (ADAM-8+/+). After allergen exposure, 
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BAL displayed an increase of eosinophil counts in ADAM-8+/+ while allergen-induced 
eosinophil BAL infiltration expressed as absolute value or percentage was lower in 
ADAM-8-/- mice (p<0.0005) (table 2). Bronchial inflammation was also studied by 
histology. Upon allergen exposure, ADAM-8-/- mice displayed far less peribronchial 
inflammation than ADAM-8+/+ mice (p<0.0005) (figure 2 E-H and K). Peribronchial 
tissue was specifically evaluated regarding eosinophil infiltration by histology and 
specific staining. After allergen exposure, eosinophil counts in airway walls were 5 
times lower in ADAM-8-/- mice  as compared to ADAM-8+/+ (p<0.0005) (figure 2 I-J 
and L). 
Cytokine measurements by protein arrays and ELISA 
As cytokines are key mediators in the development of the asthmatic phenotype, a 
cytokine array was performed on lung tissues in ADAM-8-/- mice and WT mice after 
acute allergen exposure. Among measured cytokines, CCL11 and CCL22 levels 
were found to be significantly lower after allergen exposure in ADAM-8-/- as 
compared to ADAM-8+/+ (data not shown). These data were confirmed by ELISA 
(p<0.0005) (figure 3A-B). In mice exposed to OVA, CCL22 levels were positively 
correlated with eosinophil counts in the lung tissues (r=0.7598 and p=0.0004, 
(figure3E)). The modulation of CCL11 and CCL22 by ADAM-8 depletion has also 
been observed in our study based on ADAM-8 blockade by antibody injection 
(p<0.05) (figure 3C-D). Prototypical Th2 cytokines IL-4, IL-5 and IL-13 have been 
assessed by ELISA in whole lungs extracts and did not display significant changes 





Determination of dendritic cells recruitment in lung parenchyma in ADAM-8-/- animals 
As CCL22 is mainly secreted by dendritic cells and macrophages, an 
immunohistochemistry against CD11c and F4/80, respectively was performed on 
lung tissues in ADAM-8-/- mice  as compared to ADAM-8+/+ after allergen exposure. 
Numbers of dendritic cells and alveolar macrophages positive for this staining were 
significantly decreased in ADAM-8–/– mice as compared to ADAM-8+/+ after allergen 
exposure (figure 4 A-D). This suggests that lower levels of CCL22 are the 
consequence of a significant decrease of the two most important CCL22-producing 
cells in lung parenchyma from ADAM-8 deficient mice exposed to allergens. 
ADAM-8 expression in lung dendritic cells 
In order to verify the potential implication of ADAM-8 in immunological processes 
leading to asthma-related acute inflammation, we performed a RT-PCR on mRNA 
from dendritic cells extracted from lungs of mice acutely exposed to allergens. Levels 
of mRNA coding for ADAM-8 were higher in allergen-exposed mice as compared to 
control mice (figure 4E-F), suggesting that ADAM-8 might be a key regulator of 
dendritic cells behavior. Additionally, ADAM-8 expression was assessed by RT-PCR 
in other major cellular sources in the lung such as epithelial cells, eosinophils, 




We designed the present study to investigate the potential role of the 
metalloproteinase ADAM-8 in allergen-induced airway diseases. Through genetic 
and pharmacological approaches in two different strains of mice (Balb/c, Th2-prone 
and C57Bl/6, Th1-prone), we report that ADAM-8 significantly contributes to the 
establishment of acute allergen-induced inflammation in asthma. This novel concept 
is based on the findings that anti-ADAM-8 antibody-treated mice and ADAM-8-
deficient mice displayed significantly decreased levels of allergen-induced acute 
inflammation in BAL and in peribronchial areas. We also report for the first time that 
ADAM-8 is overexpressed in lung dendritic cells after allergen exposure. Moreover, 
we found increased levels of CCL11 and CCL22 after allergen exposure in ADAM-
8+/+ mice while these two cytokines failed to increase in ADAM-8-/- animals displaying 
therefore levels similar to sham-exposed mice for those two cytokines. We also 
reported a decrease of CCL11 and CCL22 production in anti-ADAM-8-treated mice. 
To explore the mechanism leading to a decrease of CCL22, we measured the 
numbers of dendritic cells and alveolar macrophages in the lung parenchyma and 
described a significant decrease of those two cell types in lungs of ADAM-8-/- 
animals. Moreover, CCL22 levels were highly correlated to eosinophilic inflammation 
in allergen-exposed animals. Finally, we also demonstrate that the expression and 
production of ADAM-8 proteinase were not chronically modulated in chronic asthma 
and therefore could not play significant roles in remodeling processes linked to 
asthma.  
These novel findings are in accordance with emerging data on the implication of 
ADAM-8 in the pathogenesis of pulmonary diseases [28] and suggest that ADAM-8 
might be a key regulator of dendritic cells and alveolar macrophages homeostasis. 
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From these data, one can speculate that ADAM-8 could play a significant role in 
asthma. This assumption is supported by the observation of increased levels of 
ADAM-8 mRNA expression in induced sputum cells and endobronchial biopsies from 
human asthmatics [12, 29] and previous authors have reported that ADAM-8 is 
overexpressed in mouse models of asthma. We demonstrate that ADAM-8 depletion 
modifies asthma phenotype. However, the precise mechanisms that could account 
for this ADAM-8 overexpression in asthma and its role as an effector are not yet 
completely dissected. Our data suggest that ADAM-8 might be essential for dendritic 
cells accumulation in lung parenchyma although other mechanisms such as a 
relationship between ADAM-8 and several interleukins (IL-4, IL-13) or related 
intracellular activation pathways (STAT-6) might also interfere with bronchial 
inflammation [21].  A genomic study recently reported a link between ADAM-8 single 
nucleotide polymorphisms and asthma in humans [30]. In addition, two separate 
genome-wide searches performed on mice subjected to allergen exposure 
discriminated ADAM-8 as a valid marker of allergen-induced inflammation [20, 21]. 
Interestingly, one of these studies compared different durations of exposure to 
allergens and reported that ADAM-8 was overexpressed only in acute models while 
ADAM-8 overexpression was not reported after chronic allergen exposures [20]. In 
line with this recent study of Di Valentin et al who performed microarray studies, we 
emphasized the role of ADAM-8 in acute inflammation and not in chronic remodeling 
associated to asthma. Moreover, this is in keeping with the findings of Matsuno et al 
who showed that ADAM-8 levels are increased in patients suffering from acute 
eosinophilic pneumonia but not chronic idiopathic eosinophilic pneumonia [31]. In our 
study, we report that there is less eosinophilia in the BAL in ADAM-8 KO mice. As a 
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consequence of these huge variations in eosinophil counts, we also found that total 
cell counts were significantly decreased in ADAM-8 KO animals.  
Since there is no difference in features of chronic remodeling established between 
ADAM-8 deficient mice and wild-type mice exposed to allergens, we hypothesize that 
ADAM-8 is only implicated in acute airway inflammation. ADAM-8 cleaves various 
key molecules in inflammatory processes including CD23, pro-TNF-α and L-selectin 
[25, 26]. From this substrate specificity, it can be deduced that ADAM-8 might be an 
effector in immunological processes [22, 29]. However, ADAM-8-/- mice did not 
display any developmental abnormalities and their immune system was previously 
reported as not impaired by ADAM-8 gene deletion [32]. We verified that 
unchallenged ADAM-8-/- mice bear normal eosinophil percentages in their blood by 
studying blood smears (data not shown).  
Our experiments using ADAM-8-/- animals and anti-ADAM-8 treatment demonstrate 
that ADAM-8 is per se responsible for a significantly increased allergen-induced 
acute inflammation both in lung tissue and BAL. In order to rule out the potential role 
of mice genetic background in our results, we compared the Th2-prone strain Balb/c 
with Th1-prone C57Bl/6 in the antibody-blocking experiment and we report similar 
decreases of lung inflammation. This validates our study on ADAM-8 genetically 
depleted mice performed on a Th1-prone background (129/Ola; C57Bl/6 mixed 
genetic background as most of KO mice). These experiments allow us to 
demonstrate that the effects of ADAM-8 depletion reported in the present study are 
not restricted to a specific strain and probably correspond to a conserved 
mechanism. In a first approach, our results could seem in apparent discrepancy with 
those generated by Matsuno et al [22] using mice overexpressing soluble ADAM-8 in 
the liver. Indeed, these authors reported that sADAM-8 overexpressing mice were 
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protected from the development of histological inflammation when subjected to 
asthma induction (noteworthy, these authors did not find any variation of BAL 
inflammation) [22]. However, transgenic mice used by these previous authors 
express normal levels of membrane-bound ADAM-8 in their tissues and have an 
excess of sADAM-8 in their plasma, released from the liver, rendering the final 
picture far more complex than targeted gene deletion. Moreover, one cannot exclude 
the possibility that, in this setting, sADAM-8 might display some specific biological 
activities different from membrane-bound ADAM-8.   
Mechanisms that could explain such a decrease in eosinophils as we observed in 
ADAM-8-/- and anti-ADAM-8-treated mice could be linked to a decreased production 
of CCL11 and CCL22, two chemo-attractants for eosinophils [33, 34]. CCL22, 
referred to as macrophage-derived chemokine (MDC), also takes part to Th2 
inflammation. Interestingly, immunostainings performed in humans and mice 
suggested that cells producing ADAM-8 are mostly eosinophils [21, 29]. As CCL11 
(eotaxin-1) is mainly secreted by eosinophils, a significant decrease of those cells, as 
reported in the present study might account per se for lower levels of CCL11 found 
after ADAM-8 inhibition. By contrast, CCL22 is mostly produced by macrophages and 
dendritic cells [35, 36] and appears to play a central role in allergen-induced 
inflammation since it is produced by Th2-induced dendritic cells [37]. As 
demonstrated in this study, number of  macrophages and dendritic cells present in 
lung tissue in allergen-exposed ADAM-8-/- mice is lower than ADAM-8+/+ mice.  
Very recently, other authors have reported that ADAM-8 is detectable in bronchial 
epithelium and smooth muscle cells [38]. In contrast with these observations, our own 
findings, in line with those of King et al who performed in situ hybridization, indicate 
that ADAM-8–expressing cells are mostly eosinophils and macrophages [21]. This 
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might be the consequence of technical issues (e.g. antibodies used by previous 
authors are different). However, one cannot exclude that ADAM-8 expressed by 
structural cells might play a significant role in the modulation of inflammation. One 
argument to state that stromal cells such as fibroblasts probably do not participate in 
the ADAM-8 production in an important proportion is that immunohistochemistry 
performed on lung sections do not display an important staining in these cells. In the 
present study, we measured the ADAM-8 expression by alveolar macrophages and 
interstitial macrophages since those two subtypes have recently been described to 
play very different roles in asthma pathology. We found that these two subtypes 
express ADAM-8 without obvious difference.  
Our results are in accordance with a very recent paper published on-line during the 
revision period of this manuscript and reporting that genetic depletion of ADAM-8 is 
protective against main features of asthma [39]. 
We conclude that ADAM-8 is not only a marker of allergen-induced acute 
inflammation but probably also an effector since its depletion impairs the 
development of eosinophilic inflammation through decreasing lung dendritic cells and 
alveolar macrophages and modulating CCL11 and CCL22 production. 
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Material and Methods 
Experimental asthma protocol 
Six to 8 weeks old Balb/c male mice were provided by the animal house of the 
University of Liège (Belgium). ADAM-8 deficient mice and corresponding wild-type 
mice were kindly provided by Dr. Andrew Docherty (UCB-Celltech, Slough, UK). 
ADAM-8 knock-out (KO) mice display a 129/Ola; C57/BL/6 mixed genetic 
background and only brethren were used. We used only male ADAM-8 KO mice or 
controls in our experimental procedures. In order to perform a genotyping to ensure 
that animals were homozygous KO or homozygous WT before entering our 
experimental protocols, DNA was obtained from mice tails by “Machery-Nagel 
Nucleospin®Tissue” kit. Primer pair used to distinguish KO and WT is: 
CACTGTTGGACTGGCTAAGGTG and GACATCGGTAACATTGGTCAG. Protocols 
used in this study were approved by the Ethical Committee (University of Liège, 
Belgium). Concerning the acute inflammation model, male mice were sensitized by 
intraperitoneal injections of 10 µg OVA (Sigma Aldrich, Schnelldorf, Germany) 
complexed with aluminium hydroxide (Perbio, Erembodegem, Belgium) on days 0 
and 7. From days 21 to 25, mice were challenged daily by OVA 1% aerosols for 30 
minutes. In the control group, mice were exposed to PBS aerosols. Mice were 
sacrificed 24 hours after the last allergen exposure. For the remodeling model, mice 
were sensitized by intraperitoneal injections on days 0 and 11, and groups of mice 
were exposed to OVA or PBS aerosols 5 days per week (odd weeks) from days 22 to 
96. As described in the “acute inflammation model”, mice were sacrificed 24h after 
the last allergen exposure. We used OVA from one single batch that has been 
characterized regarding endotoxin content. We have performed endotoxin 
measurement (Lonza, Braine-l’Alleud, Belgium). Mean measured endotoxin levels in 
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the current batch of OVA are 0.236 ng of endotoxin/gr of OVA. We also ensured that 
PBS used in our experiment was endotoxin-free (manufacturer specifications indicate 
no detectable levels of endotoxin).  
ADAM-8 blockade by antibody treatment 
On days 0 and 7, male Balb/c and C57Bl/6 mice were sensitized by intraperitoneal 
injections of 10 µg OVA (Sigma Aldrich, Schnelldorf, Germany) complexed with 
aluminium hydroxide (Perbio, Erembodegem, Belgium). From day 21 and for 3 
consecutive days, mice were exposed to OVA for 30 minutes. Two hours before each 
allergen challenge, intravenous injection was performed with either 25 µg anti-ADAM-
8 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) or control IgG 
antibody (R&D Systems, Minneapolis, MN, USA). Mice were sacrificed 24 h after the 
last allergen exposure. 
Bronchoalveolar lavage fluid (BALF) 
After sacrifice, a canula was inserted in the trachea of the mouse and BALF was 
performed manually by instillation of 4x1ml of PBS-EDTA 0.05mM (Calbiochem, 
Darmstadt, Germany). BAL was subjected to centrifugation for 10 minutes at 4°C and 
at 282 x g. Supernatants were stored at -80°C for future assessments while cell 
pellets were resuspended in 1ml PBS-EDTA 0.05mM in order to proceed with total 
and differential cell counts. Total cell number was measured by using a Z2 coulterΧ® 
particle count and size analyzer (Beckman Coulter, Analis, Namur, Belgium) and 
differential cell count was assessed by a skilled observer blinded to experimental 
details, based on morphological criteria. For this purpose, cells were centrifuged 
(cytospin) on a slide and stained with Diff Quick® (Dade, Brussels, Belgium).    
Lung tissue processing 
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After recovering the BAL, thorax was opened and left lung was clamped. The right 
lung was cut and snap frozen in liquid nitrogen for RNA and protein extraction 
whereas the left lung was insufflated at constant pressure with 4% paraformaldehyde 
and then embedded in paraffin for histological analysis.  
Histological analysis 
Histological analyses were performed on 5 µm lung tissue sections. Sections were 
stained with hematoxylin and eosin and a peribronchial inflammation score was 
applied to each slide as previously reported [5]. Briefly, score 0 was assigned for 
bronchi with no mononuclear cell infiltration; score 1 corresponded to few 
mononuclear cells, score 2 was assigned if there were from 1 to 5 layer(s) of 
inflammatory cells around bronchi, and score 3 was chosen when thickness of 
inflammatory cells layer was > 5 cells and surrounded the entire bronchus. Six 
bronchi per mice were counted and statistical analysis was performed by using 
GraphPad Program. In order to visualize peribronchial eosinophilic infiltration, Congo 
Red staining was performed on slides. Peribronchial eosinophils were counted for 6 
bronchi/mouse and those counts were reported to the perimeter of basal membrane 
epithelium measured with ImageJ Program. Statistical analysis was carried out using 
GraphPad software. Glandular cells were assessed using the Perodic Acid Shiff 
(PAS) staining. In order to detect peribronchial collagen deposition, Masson’s 
Trichrome staining was carried out. 
For ADAM-8 protein detection, slides were deparaffinized and, after treatment with 
Target Retrieval Solution (Dako, Glostrup, Denmark), endogenous peroxidases were 
blocked with H2O2 3% (Merck, Darmstadt, Germany). Slides were then incubated 
with goat anti-ADAM-8 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
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USA) diluted at 1:500. After rinsing, rabbit anti-goat biotin coupled secondary 
antibody was applied on the slides followed by incubation with streptavidin/HRP 
(horse radish peroxydase) complex (Dako, Glostrup, Denmark). Peroxidase activity 
was revealed using the 3-3’ diaminobenzidine hydrochlorid kit (DAB, Dako, Glostrup, 
Denmark).  
For dendritic cells and alveolar macrophages detection, slides were deparaffinized 
and, after treatment with trypsin 0.1% (Sigma-Aldrich, Schnelldorf, Germany), 
endogenous peroxidases were blocked with H2O2 3% (Merck, Darmstadt, Germany). 
Slides were then incubated with hamster anti-CD11c (Abcam, Cambridge, UK) 
diluted 1:50 or rat anti-F4/80 antibody (Serotec, Düsseldorf, Germany) diluted at 
1:100. After rinsing, goat anti-hamster or rabbit anti-rat biotin coupled secondary 
antibody was applied on the slides followed by incubation with streptavidin/HRP 
(horse radish peroxydase) complex (Dako, Glostrup, Denmark). Peroxidase activity 
was revealed using the 3-3’ diaminobenzidine hydrochlorid kit (DAB, Dako, Glostrup, 
Denmark).  
 Lung RNA/protein extraction 
Tissues were disrupted and completely homogenized forming a powder by a 
combination of turbulence and mechanical shearing and total RNA was extracted 
using RNeasy Mini kit following manufacturer’s instructions (Qiagen, Gmbh D, Hilden, 
Germany). Total protein extracts were prepared by incubating crushed lung tissues in 





To obtain single-lung-cell suspensions, lungs were perfused with 5 ml PBS through 
the right ventricle, cut into small pieces, and digested for 1 hour at 37°C in 1 mg/ml 
collagenase A (Roche, Mannheim, Germany) and 0.05 mg/ml DNaseI (Roche, 
Mannheim, Germany) in HBSS. Lung DCs were isolated using criteria of 
CD11c+/F4/80- cells, as previously described by Bedoret et al [40].	  Cells were sorted 
by flow cytometry (FACSAria). The purity of isolated dendritic cells is about 91%. 
Alveolar macrophages (AM) and interstitial macrophages (IM) were isolated using 
following criteria: CD11c+/F4/80+ cells, and CD11c-/F4/80+ cells, respectively. 
Eosinophils were isolated using criteria GR1+/CCR3+ while epithelial cells were 
isolated using laser capture microdissection (LCM) system (Leica). 
Semi-quantitative RT-PCR 
ADAM-8 mRNA expression levels were investigated by semi-quantitative RT-PCR 
using the GeneAmp thermostable RNA RT-PCR kit (Applied Biosystems, Foster City, 
CA, USA). The design of oligonucleotides for ADAM-8 was based on the sequence 
available in the Genbank: 5’-ACATTGGTCAGGCAGCCTGTCT-3’ (antisense) and 5’-
CTGTGAATCAGGACCACTCCAA-3’ (sense). The specificity of the selected 
sequences was verified using the NCBI BLASTN program 
(http://www.ncbi.nlm.nih.gov/BLAST/) and oligonucleotides were obtained from 
Eurogentec (Seraing, Belgium). RT was performed on 10 ng total RNA at 70°C 
during 15 minutes. PCR amplification conditions were optimized so that PCR 
products do not reach any saturation levels. Amplification started at 94°C for 15 
seconds, 64°C for 20 seconds, and 72° for 10 seconds for 28 cycles, followed by 2 
minutes at 72 °C. Products were then resolved on polyacrylamide gels (10%) and 
stained with Gel Star (Biowhittaker, Rockland, MD, USA). Analysis of the intensity of 
band was realized using Quantity One software (Biorad, Hercules, CA, USA). To 
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normalize mRNA levels in different samples, the value of the band corresponding to 
each mRNA level was divided by the intensity of the corresponding 28S rRNA band. 
In order to verify the specificity of amplification, PCR products were digested with 
appropriate restriction enzymes. 
Western Blotting 
Total protein extracts (20µg) were separated under reducing conditions on 12% 
polyacrylamide gels and transferred on PDVF membranes (Perkin Elmer Life 
Sciences, CA, USA). PVDF membranes were then blocked with PBS containing 10% 
milk and Tween 20 (0.1%) (Merck, Darmstadt, Germany). The primary antibody anti-
ADAM-8 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) diluted at 1:1500 was 
applied on membranes overnight at 4°C. After several washes, proteins were 
incubated with the secondary antibody conjugated with HRP (rabbit anti-goat) diluted 
at 1:2000 for 1 hour at room temperature (RT). The enhanced chemiluminescence 
(ECL) detection kit (Perkin Elmer Life Sciences, Boston, MA, USA) allowed 
visualization of immunoreactive proteins. Results were expressed as ratio between 
measured protein levels and corresponding actin levels used as loading control. 
Cytokine Array 
Detection of multiple cytokines in tissue lysates was achieved using the RayBiotech 
kit (RayBio Mouse Cytokine Antibody Array C series 1000, RayBiotech, Inc Norcross, 
GA, USA). Succinctly, array membranes were incubated with samples (pooled 
ADAM-8 KO OVA proteins (n=5) versus pooled ADAM-8 WT OVA proteins (n=5)). 
Then, a cocktail of biotin-labeled antibodies was applied on the membranes binding 
cytokines. Finally, array membranes were incubated with HRP-conjugated 




ELISA measurement of CCL11 and CCL22 was performed on lung tissue lysates of 
anti-ADAM-8-treated mice and corresponding control mice but also ADAM-8 KO and 
corresponding wild-type mice. Briefly, microwell strips were coated with an anti-
CCL11 or an anti-CCL22 murine monoclonal antibody (R&D Systems, Minneapolis, 
MN, USA) overnight. Samples were then added to the wells and incubated with the 
biotinylated antibody (R&D Systems, Minneapolis, MN, USA) for 2 hours at room 
temperature (RT). HRP-conjugated streptavidin was applied on samples before 
signal revelation.  
Statistical analysis 
Results were expressed as mean ± SEM. Statistical test was assessed on 
experimental groups using Mann-Whitney test. Correlations were sought by 
calculating Spearman’s coefficient of correlation. These tests were performed using 
GraphPad InStat software (http://www.graphpad.com/instat). Graphs were obtained 
using GrahPad Prism software (http://www.graphpad.com/prism). P values < 0.05 
were considered as significant.  
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Figure legends and Tables 
Figure 1: ADAM-8 expression and production in the lungs of mice acutely exposed to 
an allergen and after long-term allergen exposure in the chronic remodeling model.  
(A) A representative example of semi-quantitative RT-PCR for ADAM-8 in whole lung 
homogenates in acute inflammation and chronic remodeling models (Balb/c mice) 
induced by OVA; PBS serves as a control. (B) A representative Western blot of 
ADAM-8 production in acute inflammation and chronic remodeling models (Balb/c 
mice). Actin serves as a loading control. (C) ADAM-8 mRNA levels in the lungs of 
mice exposed to OVA (n=15) and control PBS-treated mice (n=16) in an acute 
inflammation model.  Results are expressed as mean ± SEM. *** p< 0.0005, Mann 
Whitney test. (D) ADAM-8 protein levels in the lungs of mice exposed to ovalbumin 
(OVA) (n=6) and control PBS-treated mice (n=6) in an acute inflammation model 
quantified by densitometrically scanning Western blots shown in (B). Results are 
expressed as mean ± SEM. * p< 0.05, Mann Whitney test. (E) Anti-ADAM-8 
immunostaining in lung tissue after acute allergen exposure (magnification, X200). 
ADAM-8 expression is stained in brown and the peribronchial area is indicated by an 
arrow. Each experiment (acute inflammation and remodeling models) was performed 
twice with n=6 to 8 mice per group per experiment.  
Figure 2: Impact of the anti-ADAM-8 antibody and depletion of ADAM8 on acute 
allergen-induced inflammation in mice. 
(A-C)  Balb/c or (D) Balb/c and C57Bl/6 mice were sensitized and exposed to OVA 2 
hours after treatment with either IgG isotype control (n=6) or anti-ADAM-8 antibody 
(n=6). (A) Eosinophil counts presented as the percentage of eosinophils within 300 
cells  of the BALF of mice after treatment with anti-ADAM-8 antibody; mean ± SEM. * 
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p< 0.05, Mann Whitney test. (B) Peribronchial eosinophilic infiltration; mean ± SEM. 
*** p< 0.0005, Mann Whitney test. (C) A representative Western blot of ADAM-8 
production in whole lung homogenates from mice treated with an anti-ADAM-8 
antibody or an isotype control. (D) Relative inhibition of eosinophilia by anti-ADAM-8; 
mean ± SEM (A-D) Data are representative of two independent experiments. 
(E-J) Histological analysis of lung tissues in ADAM-8-deficient (KO) mice acutely 
exposed to an allergen (OVA). (E-H) Representative paraffin sections after 
hematoxilin-eosin staining (magnification, 200x). (I-J) Representative paraffin section 
of lung tissue showing bronchi after congo red staining (magnification, 400x).  The 
red staining (arrow) shows eosinophil cells. (K) Quantification of peribronchial 
inflammation score in the lung samples of WT and KO mice,acute inflammation 
model (n=8 mice per group); mean ± SEM. *** p< 0.0005, Mann Whitney test. (L) 
Quantification of eosinophil numbers normalised to bronchial perimeter expressed as 
mm basement membrane in lung samples of all in WT and KO mice, acute 
inflammation model (n=8 mice per group); mean ± SEM *** p< 0.0005, Mann Whitney 
test. 
Each experiment of allergen-induced inflammation has been performed twice (n=8 
mice per group in each experiment.    
Figure 3: Measurements of CCL11 and CCL22 levels in ADAM-8+/+ and ADAM-8-/- 
mice. (A-D) CCL11 and CCL22 levels in whole lung homogenates in ADAM-8 KO 
mice (n=8 mice per group) and anti-ADAM-8-treated mice (n=6 mice per group) 
acutely challenged with OVA as determined by ELISA.; mean ± SEM, * p< 0.05; ** 
p<0.005; *** p<0.0005, Mann Whitney test. (E) Relationship between lung tissue 
CCL22 levels and lung eosinophilic infiltration in ADAM-8+/+ and ADAM-8-/- mice 
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exposed to ovalbumin; r=0.7598 p=0.0004 (Spearman correlation coefficient). (F-H) 
Levels of the main Th2 cytokines are not modulated in whole lung homogenates in 
ADAM-8 KO animals. Results are expressed as mean ± SEM (Mann Whitney test). 
Each experiment has been performed in duplicate. 
Figure 4: Recruitment of dendritic cells and alveolar macrophages in lung 
parenchyma. (A) A representative staining against F4/80 (magnification, 400x) and 
two representative examples of staining against CD11c (magnification, 400x) in 
alveolar (left) and peribronchial (right) areas in ADAM-8+/+ mice exposed to OVA. 
Positive staining is shown in brown. (B, C) Quantification of dendritic cell and 
macrophage numbers in lung parenchyma expressed in cell number per field (n=8 in 
each group); Results are expressed as mean ± SEM, * p< 0.05; ** p< 0.005, Mann 
Whitney test. (D) The percentage of dendritic cells among the total cell population 
recovered in the whole lung homogenates as determined by flow cytometry (right 
panel). Data are mean ± SEM, * p< 0.05; ** p< 0.005, Mann Whitney test (n=8). 
Representative flow cytometry plots of CD11c+/F4/80- cells for ADAM-8 KO mice 
after allergen exposure (left panel, percentages indicated). (E) Representative 
ADAM-8 mRNA expression as determined by RT-PCR using dendritic cells from the 
lungs of mice acutely exposed to an allergen (OVA). (F) ADAM-8 mRNA expression 
in lung dendritic cells in acute inflammation model (n=4 mice). Results are expressed 
as mean ± SEM. ** p< 0.005, Mann Whitney test. (G) ADAM-8 mRNA expression in 
EC (epithelial cells), EO (eosinophils), AM (alveolar macrophages) and IM (interstitial 
macrophages) isolated from the lung of Balb/c mice. 




Table : Cell counts in bronchoalveolar lavages in anti-ADAM-8-treated mice (1) and 










Results were expressed as mean ± SEM. * p< 0.05  
 
Results were expressed as mean ± SEM. * p< 0.05 versus mice exposed to PBS. ** 
p<0.005 versus mice exposed to PBS. *** p<0.0005 versus mice exposed to PBS. † 
P<0.05 versus wild-type mice exposed to PBS. ∆  p<0.0005 versus wild-type mice 
exposed to OVA.   
 
  Isotype control Anti-ADAM-8 
epithelial cells (%) 10.250±1.438 11.114±1.962 
eosinophils (%) 23.133±3.234 13.400±1.807* 
neutrophils (%) 0.483±0.158 0.542±1.125 
lymphocytes (%) 0.483±0.253 0.257±0.069 
macrophages (%) 65.517±3.164 74.543±2.122* 
total cells (103/ml) 41.855±5.844 32.065±9.626 
epithelial cells (103/ml) 4.407±0.922 5.301±2.618 
eosinophils (103/ml) 11.078±2.455 4.982±1.189 
neutrophils (103/ml) 0.248±0.081 0.166±0.046 
lymphocytes (103/ml) 0.232±0.156 0.163±0.070 
macrophages (103/ml) 25.835±3.493 25.947±7.081 
 WT PBS WT OVA KO PBS KO OVA 
epithelial cells (%) 12.000±1.872 1.860±0.504*** 15.575±1.388 7.589±1.075***, ∆ 
eosinophils (%) 0.578±0.434 69.750±2.323*** 1.525±0.584 20.939±4.886***, ∆ 
neutrophils (%) 0.001±0.001 0.850±0.432 0.037±0.026 0.672±0.339 
lymphocytes (%) 0.033±0.033 0.260±0.137 0.001±0.001 0.211±0.091 
macrophages (%) 87.311±1.822 27.180±2.132*** 82.394±1.531 70.439±4.416*, ∆ 
total cells (103/ml) 21.872±3.820 145.820±30.394*** 44.464±13.122 27.816±2.930*** 
epithelial cells (103/ml) 2.230±0.269 2.919±1.376 5.714±0.953† 2.239±0.397** 
eosinophils (103/ml) 0.133±0.104 103.660±22.198*** 1.100±0.579 6.095±2.089***, ∆ 
neutrophils (103/ml) 0.001±0.001 0.547±0.251 0.049±0.043 0.111±0.050 
lymphocytes (103/ml) 0.007±0.006 0.362±0.242 0.001±0.003 0.050±0.024 
macrophages (103/ml) 14.621±3.701 29.594±7.305 30.908±9.810 16.529±2.310 
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